MedTrace Logo

(RIGHT HEART III Study - Right Ventricular Hemodynamic Evaluation and Response to Treatment)

NCT03362047 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2025-03-30

No results posted yet for this study

Summary

Pilot study to determine the therapeutic effect of two prarallel groups treated with either Riciguat or Macitentan, evaluated by the change in systolic and diastolic RV function within 12 weeks after first drug intake in order to plan a larger Phase II study.

Conditions

  • Pulmonary Arterial Hypertension (PAH)

Interventions

DRUG

Riciguat Group

Patients will be administered 12 weeks Riciguat

DRUG

Macitentan Group

Patients will be administered 12 weeks Macitentan

Sponsors & Collaborators

  • Philipps University Marburg

    collaborator OTHER

  • University of Giessen

    lead OTHER

Principal Investigators

  • Werner Seeger, Prof · University Gießen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-01
Primary Completion
2024-07-03
Completion
2024-08-14

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03362047 on ClinicalTrials.gov